Literature DB >> 28137799

Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus.

Maryam Ehteshami1, Sijia Tao1, Keivan Zandi1,2, Hui-Mien Hsiao1, Yong Jiang1, Emily Hammond1, Franck Amblard1, Olivia O Russell1, Andres Merits3, Raymond F Schinazi4.   

Abstract

Chikungunya virus (CHIKV) represents a reemerging global threat to human health. Recent outbreaks across Asia, Europe, Africa, and the Caribbean have prompted renewed scientific interest in this mosquito-borne alphavirus. There are currently no vaccines against CHIKV, and treatment has been limited to nonspecific antiviral agents, with suboptimal outcomes. Herein, we have identified β-d-N4-hydroxycytidine (NHC) as a novel inhibitor of CHIKV. NHC behaves as a pyrimidine ribonucleoside and selectively inhibits CHIKV replication in cell culture.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Chikungunya virus; antiviral agents; nucleoside analogs; replicon

Mesh：

Substances：

Year:  2017        PMID： 28137799      PMCID： PMC5365705          DOI： 10.1128/AAC.02395-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 2.  Chikungunya virus pathogenesis: From bedside to bench.

Authors:  Thérèse Couderc; Marc Lecuit
Journal:  Antiviral Res       Date:  2015-07-06       Impact factor: 5.970

3.  Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.

Authors:  Leen Delang; Nidya Segura Guerrero; Ali Tas; Gilles Quérat; Boris Pastorino; Mathy Froeyen; Kai Dallmeier; Dirk Jochmans; Piet Herdewijn; Felio Bello; Eric J Snijder; Xavier de Lamballerie; Byron Martina; Johan Neyts; Martijn J van Hemert; Pieter Leyssen
Journal:  J Antimicrob Chemother       Date:  2014-06-20       Impact factor: 5.790

4.  Design and Validation of Novel Chikungunya Virus Protease Inhibitors.

Authors:  Pratyush Kumar Das; Laura Puusepp; Finny S Varghese; Age Utt; Tero Ahola; Dzmitry G Kananovich; Margus Lopp; Andres Merits; Mati Karelson
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 5.  Chikungunya: a potentially emerging epidemic?

Authors:  Michelle M Thiboutot; Senthil Kannan; Omkar U Kawalekar; Devon J Shedlock; Amir S Khan; Gopalsamy Sarangan; Padma Srikanth; David B Weiner; Karuppiah Muthumani
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

6.  Ribavirin therapy for Chikungunya arthritis.

Authors:  Rajan Ravichandran; Manju Manian
Journal:  J Infect Dev Ctries       Date:  2008-04-01       Impact factor: 0.968

7.  Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.

Authors:  Maryam Ehteshami; Sijia Tao; Tugba Ozturk; Longhu Zhou; Jong Hyun Cho; Hongwang Zhang; Sheida Amiralaei; Jadd R Shelton; Xiao Lu; Ahmed Khalil; Robert A Domaoal; Richard A Stanton; Justin E Suesserman; Biing Lin; Sam S Lee; Franck Amblard; Tony Whitaker; Steven J Coats; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs.

Authors:  Alexander Karlas; Stefano Berre; Thérèse Couderc; Margus Varjak; Peter Braun; Michael Meyer; Nicolas Gangneux; Liis Karo-Astover; Friderike Weege; Martin Raftery; Günther Schönrich; Uwe Klemm; Anne Wurzlbauer; Franz Bracher; Andres Merits; Thomas F Meyer; Marc Lecuit
Journal:  Nat Commun       Date:  2016-05-12       Impact factor: 14.919

9.  Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.

Authors:  Lisa Henß; Simon Beck; Tatjana Weidner; Nadine Biedenkopf; Katja Sliva; Christopher Weber; Stephan Becker; Barbara S Schnierle
Journal:  Virol J       Date:  2016-08-31       Impact factor: 4.099

10.  Trigocherrierin A, a potent inhibitor of chikungunya virus replication.

Authors:  Mélanie Bourjot; Pieter Leyssen; Johan Neyts; Vincent Dumontet; Marc Litaudon
Journal:  Molecules       Date:  2014-03-24       Impact factor: 4.411
View more
  30 in total

1.  β-d-N 4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.

Authors:  Nadya Urakova; Valeriya Kuznetsova; David K Crossman; Arpine Sokratian; David B Guthrie; Alexander A Kolykhalov; Mark A Lockwood; Michael G Natchus; Michael R Crowley; George R Painter; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

Review 2.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

Review 3.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

Review 4.  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors:  Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

Review 5.  A review on structural genomics approach applied for drug discovery against three vector-borne viral diseases: Dengue, Chikungunya and Zika.

Authors:  Shobana Sundar; Shanmughavel Piramanayagam; Jeyakumar Natarajan
Journal:  Virus Genes       Date:  2022-04-08       Impact factor: 2.332

6.  Bisacodyl Limits Chikungunya Virus Replication In Vitro and Is Broadly Antiviral.

Authors:  Natalie J LoMascolo; Yazmin E Cruz-Pulido; Bryan C Mounce
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

Review 7.  Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.

Authors:  Ashley Jia Wen Yip; Zheng Yao Low; Vincent T K Chow; Sunil K Lal
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

8.  Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Authors:  Jeong-Joong Yoon; Mart Toots; Sujin Lee; Myung-Eun Lee; Barbara Ludeke; Jasmina M Luczo; Ketaki Ganti; Robert M Cox; Zachary M Sticher; Vindya Edpuganti; Deborah G Mitchell; Mark A Lockwood; Alexander A Kolykhalov; Alexander L Greninger; Martin L Moore; George R Painter; Anice C Lowen; Stephen M Tompkins; Rachel Fearns; Michael G Natchus; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 9.  Chikungunya: vaccines and therapeutics.

Authors:  Kothila Tharmarajah; Suresh Mahalingam; Ali Zaid
Journal:  F1000Res       Date:  2017-12-08

Review 10.  Nucleoside analogues for the treatment of coronavirus infections.

Authors:  Andrea J Pruijssers; Mark R Denison
Journal:  Curr Opin Virol       Date:  2019-05-21       Impact factor: 7.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.